Matthias Söhn

Matthias Söhn

Auto-generated profile, based on publicly available information

Matthias Söhn

Scientific-RT GmbH, Welserstr. 7, 81373 München, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MNMaximilian Niyazi
Maximilian Niyazi
IKIvan Karin
Ivan Karin
MSMatthias Söhn
Matthias Söhn
SNSilke B Nachbichler
Silke B Nachbichler
PLPeter Lang
Peter Lang
UGUte Ganswindt
Ute Ganswindt
Re-irradiation is a reasonable second treatment option for patients with recurrent malignant glioma (MG) after previous radio(chemo)therapy. However, only limited data is available allowing for a precise selection of patients suitable for re-treatment in regard to safety and efficacy.

10 September 2009 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
MSMatthias Söhn
Matthias Söhn
MWMartin Weinmann
Martin Weinmann
MAMarkus Alber
Markus Alber

12 December 2009 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MSMarcin Sikora
Marcin Sikora
JMJan Muzik
Jan Muzik
MSMatthias Söhn
Matthias Söhn
MWMartin Weinmann
Martin Weinmann
MAMarkus Alber
Markus Alber
The purpose of the present study is to compare finite size pencil beam (fsPB) and Monte Carlo (MC) based optimization of lung intensity-modulated stereotactic radiotherapy (lung IMSRT).

18 March 2013 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
HBHendrik Ballhausen
Hendrik Ballhausen
MRM Reiner
M Reiner
SKS Kantz
S Kantz
CBC Belka
C Belka
MSM Söhn
M Söhn
The purpose of this paper is to understand intrafraction movement as a stochastic process driven by random external forces. The hypothetically proposed three-dimensional random walk model has significant impact on optimal PTV margins and offers a quantitatively correct explanation of experimental findings. Properties of the random walk are calculated from first principles, in particular fraction-average population density distributions for displacements along the principal axes. When substituted into the established optimal margin recipes these fraction-average distributions yield safety margins about 30% smaller as compared to the suggested values from end-of-fraction gaussian fits. Stylized facts of a random walk are identified in clinical data, such as the increase of the standard deviation of displacements with the square root of time. Least squares errors in the comparison to experimental results are reduced by about 50% when accounting for non-gaussian corrections from the random walk model.

25 October 2020 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
MMMaaike T. W. Milder
Maaike T. W. Milder
MAMarkus Alber
Markus Alber
MSMatthias Söhn
Matthias Söhn
MHMischa S. Hoogeman
Mischa S. Hoogeman
Purpose: To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three‐dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA).Methods: The independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field‐size dependent corrections). A set of 84 patient‐specific quality assurance (QA) measurements for multi‐leaf collimator (MLC) plans, using an Octavius two‐dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels.Results: Of all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5‐mm fixed cone. The profiles were compared using a one‐dimensional gamma evaluation with 2% dose difference and 0.5 mm distance‐to‐agreement (Γ(2,0.5)). The off‐centre ratios showed an average pass rate >99% (92–100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans.Conclusion: The first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patient‐specific QA measurements in our clinic.

1 April 2018 in Zeitschrift für Medizinische Physik
Verified
Journal Article
Closed access
PFPhilipp Freislederer
Philipp Freislederer
CHChristian Heinz
Christian Heinz
HZHenrike von Zimmermann
Henrike von Zimmermann
SGSabine Gerum
Sabine Gerum
Falk RoederFalk Roeder
Falk Roeder
KPKatia Parodi
Katia Parodi